EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Datamonitor
Analyst
include the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companies
Articles
The Rapidly Evolving Landscape of Cancer Therapeutics
Cancer is considered as a common name to address a large group comprising more than diseases affecting several parts of the body All cancers show common characteristics such as the uncontrolled growth and proliferation of abnormal cells
Research Insights
Functional Regression Clustering with Multiple Functional Gene Expressions
Gene expression data is often collected in time series experiments under different experimental conditions There may be genes that have very different gene expression profiles over time but that adjust their gene expression patterns in the same way under experimental conditions
Case Studies
Viral Clearance For Biopharmaceutical Downstream Processes
Abstract Viral clearance studies are mandated prior to entering clinical trials and for commercial launch of biopharmaceuticals These studies are a key component of risk mitigation to reduce the potential for iatrogenic transmission of pathogenic viruses This paper reviews regulatory guidance and practical strategies for designing viral clearance studies Ess
Techno Trends
Immix Biopharma Introduces Breakthrough NXC-201 for the Treatment of Relapsed/Refractory AL Amyloidosis
Immix Biopharma has introduced NXC for the treatment of relapsedrefractory AL amyloidosis a serious and progressive disorder
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Role of Genomics in Shaping the Future of Medicine
Smita Agrawal holds a PhD in Chemical Engineering from the University of California, Berkeley. She has over 20 years of research experience in stem cell biology, neuroscience, immunology, genomics, oncology and real-world data. She currently serves as an independent consultant, offering strategic guidance and insights to life sciences companies on genomics, AI, and health care data applications.
Impact Assessment of US Tariff Threat on Indian Healthcare Export
Dr. M. Aamir Mirza is working as an Assistant Professor in the Department of Pharmaceutics, Jamia Hamdard, an NIRF Rank 1 institute and a NAAC ‘A+” grade deemed to be University. He has a multifaceted career portfolio adorned with both industry and academic accomplishments. During his industry stay he became a seasoned scientist and dealt with challenging NCE/NDA development. He is on advisory boards of some international research-based companies of India, New Zealand and Europe. Academics and Research being close to his heart, he has published more than 110 manuscripts in the journals of international repute and has been granted 02 Indian patent and filed for 04. He has contributed several chapters in books published by reputed authors like Elsevier and Bentham. He is amongst the very few scientists globally who has an expertise in Humic substances research. A well-travelled scientist; he has delivered scientific addresses in countries like USA, Austria, Japan, Netherlands, Turkey, Estonia, Spain and Russia. He has been Elite Fellow at University of Malaya (Malaysia) for the last 5 years where he takes classes on the topics related to industrial pharmacy.
APAC’s Biopharma Providers’ Role in Pioneering a Healthcare Revolution
Narayana is responsible for leading the overall business, P&L, strategy, and program management for Avantor’s Biopharma Business Unit in AMEA. He possesses close to two decades of comprehensive experience in international markets, leading diverse teams in account, product, sales and business management, and delivering strategic solutions for Consumables, systems and Instruments in Academic, Pharmaceuticals, Bioprocessing, and Bioresearch Industries.
Mussel-inspired Bio-adhesives
Amisha Raikar is a highly motivated individual with a strong educational background in the field of pharmaceutics. She completed her Bachelor of Pharmacy (B-Pharm) from Goa University in 2022, which laid the foundation for her journey into the pharmaceutical industry. Building upon her undergraduate degree, Amisha decided to pursue Master of Pharmacy (M-Pharm) in pharmaceutical science and formulation development. Recognising the importance of expanding her skill set beyond the technical aspects of pharmaceuticals, she embarked on a Postgraduate Diploma in International Business Management from the Indira Gandhi National Open University (IGNOU). Amisha's passion for learning and her desire to contribute to the field of pharmaceuticals has fueled her interest in pursuing a Ph.D. With her strong educational background, practical experience, and an eagerness to pursue further studies, Amisha Raikar is poised to make significant contributions to the field of pharmaceuticals through her future endeavours, such as a Ph.D. program.
Natural Polymers and Fibers in Drug Delivery
Dr. Meghraj V. Suryawanshi is an Associate Professor and Co-Founder of Sandip Institute of Pharmaceutical Sciences. He holds M.Pharm, MBA, PDCR, and Ph.D. degrees. With over 7 years of research experience and 4 years in teaching, his expertise lies in polymer science, novel drug delivery systems (NDDS), and intellectual property rights (IPR). Dr. Suryawanshi has authored more than 55 publications, 8 books, and holds several patents. He actively leads innovative pharmaceutical research with a strong focus on translational impact.
Akshata Yashwant Patne is a pharmaceutical nanotechnology expert with over 3 years of experience in clinical research, drug delivery, and AI-driven therapeutics. She has led nanoparticle-based studies, published peer-reviewed articles, and actively mentors students, combining science, innovation, and leadership across academia, research, and global scientific communities.
press releasesRead more...
Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases
Roche SIX RO ROP OTCQX RHHBY announced today the grand opening of the Roche Genentech Innovation Center Boston expanding Roche and Genentechs US research presence in one
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
Ultragenyx Pharmaceutical Inc NASDAQ RARE today announced that the US Food and Drug Administration FDA granted standard full approval of FAYUVI rebisufligene etisparvovechopf
Tenthpin Launches AI, IoMT-based Centre for Life Sciences Innovation Hub in Bengaluru
Switzerland based Tenthpin Management Consultants a global leader in management and technology consulting for Life Sciences companies has announced the launch of Innovation Hub in Bengaluru
Novo and Anthropic will collaborate to advance drug discovery with Claude
Novo Nordisk and Anthropic today announced a collaboration that will help Novo accelerate the development of new medicines and advance AIdriven software development
Leqembi® Pen subcutaneous formulation approved in Japan
BioArctic AB publs Nasdaq Stockholm BIOA B partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi known as Leqembi Pen in Japan has been approved as a new route of administration for the treatment of early Alzheimers disease
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Twist Bioscience Corporation NASDAQ TWST a midcap growth and value biotech company today announced an agreement with Lilly TuneLab a collaborative AIML drug discovery platform created by Eli Lilly and Company
EventsRead more...
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
22 - 24
Sep 2026InsurInnovator Connect Asia
Singapore
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
29 - 01
Sep 202610th IPF Summit 2026
Boston, MA, USA
29 - 01
Sep 2026Powtech Technopharm 2026
Nuremberg, Germany
30 - 01
Sep 2026Pharma Launch Excellence Summit
Hyatt Regency Boston Harbor, B...
LATEST NEWSRead more...
Dualitas Therapeutics and Roche Partner to Discover Bispecific Antibodies for I&I Diseases
Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody BsAb therapies for immunology and inflammation II diseases
Eisai and Biogen Receive Approval for LEQEMBI Pen for Early Alzheimer’s Disease
Eisai and Biogen have received approval in Japan for LEQEMBI Pen a subcutaneous SC formulation of lecanemab for the treatment of early Alzheimers disease AD
QurCan Therapeutics Enters into Collaboration with Lilly Advance Nucleic Acid Therapies for Nervous System Diseases
QurCan Therapeutics has entered into an exclusive research and collaboration agreement with Eli Lilly and Company to develop nucleic acid therapies for diseases affecting the central nervous system CNS and peripheral nervous system PNS
BostonGene Expands Collaboration with Dana-Farber Cancer Institute for Breast Cancer Research
BostonGene has expanded its scientific collaboration with DanaFarber Cancer Institute to study the biological mechanisms involved in breast cancers associated with BRCA and BRCA mutations
Telix Receives Approval for Pixclara for Brain Cancer Imaging
Telix Pharmaceuticals has received approval from the US Food and Drug Administration FDA for Pixclara floretyrosine F or FFET a radioactive diagnostic drug used with positron emission tomography PET to image gliomas a type of brain cancer
Evonik Expands Biotechnology Manufacturing Capacity in Slovakia
Evonik has started construction of a biotechnology expansion at its Fermas site in Slovensk upa Slovakia